The growing voice of stakeholders, from patients to payers, is changing the path of drug development. Nowhere is this trend more evident than in the oncology space. While evidence-based clinical medicine still stands as the prime driver, the additional driver that is emerging is overall treatment value. Value-based medicine is at the heart of a broadening debate on a host of topics, including the quality of cancer care, access to treatments and the differing stakeholder expectations of drug therapy.
Quintiles’ experts Brian Huber and John Doyle combine their expertise in commercialization, market access and innovation to outline the critical issues to watch. Their report demonstrates the need to converge clinical and commercial imperatives earlier within the drug development process to meet a future demand for value-based medical practices.
About the Authors
John J. Doyle, Ph.D., M.P.H.
Managing Director & Practice Leader
Dr. Doyle focuses on helping life sciences companies maximize the commercial success of their products through market access strategy and evidence-based research. Previously, he was president and a founder of Analytica International, a global reimbursement, outcomes and market access consulting firm. He previously led the Oncology and Immunology Economics Research Group at Bristol-Myers Squibb. Since 1993, Dr. Doyle has authored over 50 original research articles and abstracts, in a variety of therapeutic areas. As a health economist and epidemiologist, he has lectured on research methodologies for academic and commercial audiences in the US, Canada, Europe and Latin America. He has consulted global pharmaceutical and biotech firms on strategic concerns regarding product development, pricing, reimbursement, market valuation and other commercialization issues. Dr. Doyle received a bachelor of science degree in applied economics with a concentration in the life sciences from Cornell University. He received a master of public health degree and a doctor of public health degree in epidemiology from the Mailman School of Public Health at Columbia University.
His consulting service areas include pricing and reimbursement strategy, health economic and outcomes research evaluations, health technology assessments and scenario planning.
Vice President, Drug Development Partnerships
Dr. Huber works in the Capital group of Quintiles, bringing more than 25 years of research and management experience in major pharmaceutical companies and biotechnology companies. Dr. Huber was formerly the chief scientific officer of Adherex Technologies, a biopharma company focused on novel cancer therapeutics. Prior to joining Adherex, Dr. Huber served as vice president of biology/pharmacology in drug discovery for GlaxoSmithKline. In addition, he was responsible for chairing and managing a major joint venture between GSK and Shionogi focused on developing drugs in cancer, HIV, stroke, Alzheimer’s and inflammatory bowel disease. Dr. Huber has 10 issued US patents, eight patents pending, and has authored more than 80 peer-reviewed articles, books and book chapters. He is an adjunct professor in the Comprehensive Cancer Center at Duke University Medical Center and at The George Washington University Medical Center focused on cancer pharmacology and oncology. Dr. Huber is board-certified in clinical pharmacology and applied pharmacology and a Diplomat of the American Board of Clinical Pharmacology.